Collaborative Arrangements and Licensing Agreements, Janssen Biotech, Inc. (Details) $ in Thousands	1 Months Ended		3 Months Ended								12 Months Ended			24 Months Ended
	Jan. 31, 2018 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2017 USD ($) Program	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2017 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue earned			$ 172,299	$ 120,911	$ 104,152	$ 110,304	$ 160,349	$ 110,927	$ 38,470	$ 36,874	$ 507,666	$ 346,620	$ 283,703
Janssen Biotech, Inc. [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Number of programs under which drugs are to be developed and commercialized | Program											3
Upfront payment recorded as deferred revenue		$ 35,000
Minimum amount of payments receivable for license fees and substantive milestones			800,000								$ 800,000			$ 800,000
Maximum amount of payments receivable for development milestones			175,000								175,000			175,000
Maximum amount of payments receivable for regulatory milestones			440,000								440,000			440,000
Maximum amount of payments receivable for commercialization milestones			180,000								180,000			180,000
Cumulative payments received			61,800								61,800			61,800
License fee received														15,000
Next prospective milestone			$ 5,000								5,000			$ 5,000
Revenue earned											$ 33,500	27,300	$ 8,900
Deferred revenue							$ 17,500					$ 17,500
Janssen Biotech, Inc. [Member] | Subsequent Event [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Payment received for advancing programs	$ 5,000